Clinical Trial Update: Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov entry describes a Phase 2 study evaluating pembrolizumab in combination with dasatinib, imatinib, or nilotinib for patients with chronic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• Imatinib mesylate (Imatinib)
• Nilotinib (nilotinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING